Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients

Saved in:
Bibliographic Details
Published in:Transplantation proceedings 2000-12, Vol.32 (8), p.2757-2759
Main Authors: Sterkers, G, Baudouin, V, Ansart-Pirenne, H, Maisin, A, Niaudet, P, Cochat, P, Loirat, C
Format: Article
Language:English
Subjects:
Adolescent
Antibodies, Monoclonal - pharmacokinetics
Antibodies, Monoclonal - therapeutic use
Basiliximab
Biological and medical sciences
Child
Child, Preschool
Humans
Immunomodulators
Immunosuppressive Agents - pharmacokinetics
Immunosuppressive Agents - therapeutic use
Infant
Kidney Transplantation - immunology
Lymphocyte Count
Medical sciences
Pharmacology. Drug treatments
Prospective Studies
Receptors, Interleukin-2 - blood
Receptors, Interleukin-2 - immunology
Recombinant Fusion Proteins - pharmacokinetics
Recombinant Fusion Proteins - therapeutic use
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the urinary system
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0041-1345
1873-2623
DOI:10.1016/S0041-1345(00)01868-6